Modulation of inflammatory response after spinal cord trauma with deferoxamine, an iron chelator

Free Radical Research

Volumn 44, Issue 6, 2010, Pages 694-709

  Paterniti, Irene ^a   Mazzon, Emanuela ^b   Emanuela, Esposito ^a,b   Paola, Rosanna Di ^b   Galuppo, Maria ^a   Bramanti, Placido ^b   Cuzzocrea, Salvatore ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Apoptosis; Inflammatory mediators; SCI; Tissue damage

Indexed keywords

3 NITROTYROSINE; CHELATING AGENT; DEFEROXAMINE; FAS LIGAND; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONALDEHYDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN S 100;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DNA DAMAGE; DRUG MECHANISM; IMMUNOREACTIVITY; INFLAMMATION; MALE; MOTOR PERFORMANCE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN EXPRESSION; SPINAL CORD INJURY; THORACIC SPINAL CORD; TISSUE INJURY; TRANSCRIPTION INITIATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DEFEROXAMINE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INFLAMMATION; INFLAMMATION MEDIATORS; IRON CHELATING AGENTS; MALE; MICE; NEUTROPHIL INFILTRATION; RECOVERY OF FUNCTION; SPINAL CORD INJURIES;

MUS;

EID: 77953604105     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715761003742993     Document Type: Article

References (42)

1. Shapiro S, Borgens R, Pascuzzi R, Roos K, Groff M, Purvines S, Rodgers RB, Hagy S, Nelson P. Oscillating fi eld stimulation for complete spinal cord injury in humans: a phase 1 trial. J Neurosurg Spine 2005;2:3-10.
2. Samadikuchaksaraei A. An overview of tissue engineering approaches for management of spinal cord injuries. J Neuroeng Rehab 2007;4:15.
3. Winkler T, Sharma HS, Gordh T, Badgaiyan RD, Stalberg E, Westman J. Topical application of dynorphin A (1-17) antiserum attenuates trauma induced alterations in spinal cord evoked potentials, microvascular permeability disturbances, edema formation and cell injury: an experimental study in the rat using electrophysiological and morphological approaches. Amino Acids 2002;23:273-281.
4. Conti A, Cardali S, Genovese T, Di Paola R, La Rosa G. Role of infl ammation in the secondary injury following experimental spinal cord trauma. J Neurosurg Sci 2003;47:89-94.
5. Knoblach SM, Huang X, VanGelderen J, Calva-Cerqueira D, Faden AI. Selective caspase activation may contribute to neurological dysfunction after experimental spinal cord trauma. J Neurosci Res 2005;80:369-380.
6. Liu JB, Tang TS, Xiao DS. Changes of free iron contents and its correlation with lipid peroxidation after experimental spinal cord injury. Chin J Traumatol 2004;7:229-232.
7. Yu J, Guo Y, Sun M, Li B, Zhang Y, Li C. Iron is a potential key mediator of glutamate excitotoxicity in spinal cord motor neurons. Brain Res 2009;1257:102-107.
8. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990;50:4929-4930.
9. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
10. Gu Y, Hua Y, Keep RF, Morgenstern LB, Xi G. Deferoxamine reduces intracerebral hematoma-induced iron accumulation and neuronal death in piglets. Stroke 2009;40: 2241-2243.
11. Okauchi M, Hua Y, Keep RF, Morgenstern LB, Xi G Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke 2009;40:1858-1863.
12. Sirin BH, Ortac R, Cerrahoglu M, Saribulbul O, Baltalarli A, Celebisoy N, I kesen I, Rendeci O. Ischaemic preconditioning reduces spinal cord injury in transient ischaemia. Acta Cardiol 2002;57:279-285.
13. Mullane K. Neutrophil-platelet interactions and post-ischemic myocardial injury. Prog Clin Biol Res 1989;301:39-51.
14. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-358.
15. Bethea JR, Castro M, Keane RW, Lee TT, Dietrich WD, Yezierski R P. Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci 1998;18:3251-3260.
16. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open fi eld testing in rats. J Neurotrauma 1995;12:1-21.
17. Joshi M, Fehlings MG. Development and characterization of a novel, graded model of clip compressive spinal cord injury in the mouse: Part 2. Quantitative neuroanatomical assessment and analysis of the relationships between axonal tracts, residual tissue, and locomotor recovery. J Neurotrauma 2002;19:191-203.
18. Joshi M, Fehlings MG. Development and characterization of a novel, graded model of clip compressive spinal cord injury in the mouse: Part 1. Clip design, behavioral outcomes, and histopathology. J Neurotrauma 2002;19:175-190.
19. Nakamura T, Keep RF, Hua Y, Schallert T, Hoff JT, Xi G. Deferoxamine-induced attenuation of brain edema and neurological defi cits in a rat model of intracerebral hemorrhage. J Neurosurg 2004;100:672-678.
20. Boldt DH. New perspectives on iron: an introduction. Am J Med Sci 1999;318:207-212.
21. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994;63:793-807.
22. Fleischer JE, Lanier WL, Milde JH, Michenfelder JD. Failure of deferoxamine, an iron chelator, to improve neurologic outcome following complete cerebral ischemia in dogs. Stroke 1987;18:124-127.
23. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci 1964;119:758-768.
24. Palmer C, Roberts RL, Bero C. Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats. Stroke 1994;25:1039-1045.
25. Porter JB. Deferoxamine pharmacokinetics. Semin Hematol 2001;38:63-68.
26. Jessen KR, Mirsky R. Nonmyelin-forming Schwann cells coex-press surface proteins and intermediate fi laments not found in myelin-forming cells: a study of Ran-2, A5E3 antigen and glial fi brillary acidic protein. J Neurocytol 1984;13:923-934.
27. Ousman SS, David S. MIP-1alpha, MCP-1, GM-CSF, and TNF-alpha control the immune cell response that mediates rapid phagocytosis of myelin from the adult mouse spinal cord. J Neurosci 2001;21:4649-4656.
28. Weiss G, Werner-Felmayer G, Werner ER, Grunewald K, Wachter H, Hentze M W. Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med 1994;180:969-976.
29. Gulturk S, Kozan R, Bostanci MO, Sefi l F, Bagirici F. Inhibition of neuronal nitric oxide synthase prevents iron-induced cerebellar Purkinje cell loss in the rat. Acta Neurobiol Exp 2008;68:26-31.
30. Olas B, Nowak P, Kolodziejczyk J, Ponczek M, Wachowicz B. Protective effects of resveratrol against oxidative/nitrative modifi cations of plasma proteins and lipids exposed to perox-ynitrite. J Nutr Biochem 2006;17:96-102.
31. Endoh M, Maiese K, Wagner J. Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. Brain Res 1994;651:92-100.
32. Sato K, Tashiro Y, Chibana S, Yamashita A, Karakawa T, Kohrogi H. Role of lipid-derived free radical in bleomycin-induced lung injury in mice: availability for ESR spin trap method with organic phase extraction. Biol Pharm Bull 2008;31:1855-1859.
33. Emerit J, Beaumont C, Trivin F. Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother 2001;55:333-339.
34. Szabo C, Virag L, Cuzzocrea S, Scott GS, Hake P, O ' Connor MP, et al. Protection against peroxynitrite-induced fi broblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci USA 1998;95:3867-3872.
35. Bao X, Wu G, Hu S, Huang F. Poly(ADP-ribose) polymerase activation and brain edema formation by hemoglobin after intracerebral hemorrhage in rats. Acta Neurochir 2008;105: 23-27.
36. Wu J, Ohlsson M, Warner EA, Loo KK, Hoang TX, Voskuhl RR, Havton LA. Glial reactions and degeneration of myeli-nated processes in spinal cord gray matter in chronic experimental autoimmune encephalomyelitis. Neuroscience 2008;156: 586-596.
37. Simonart T, Degraef C, Andrei G, Mosselmans R, Hermans P, Van Vooren JP, Noel JC, Boelaert JR, Snoeck R, Heenen M. Iron chelators inhibit the growth and induce the apoptosis of Kaposi ' s sarcoma cells and of their putative endothelial precursors. J Invest Dermatol 2000;115:893-900.
38. Wilson MR. Apoptotic signal transduction: emerging pathways. Biochem Cell Biol 1998;76:573-582.
39. Nesic-Taylor O, Cittelly D, Ye Z, Xu GY, Unabia G, Lee JC, Svrakic NM, Liu XH, Youle RJ, Wood TG, McAdoo D, West-lund KN, Hulsebosch CE, Perez-Polo JR. Exogenous Bcl-xL fusion protein spares neurons after spinal cord injury. J Neu-rosci Res 2005;79:628-637.
40. Ackery A, Robins S, Fehlings MG. Inhibition of Fas-mediated apoptosis through administration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury. J Neurotrauma 2006;23:604-616.
41. Barger SW, Van Eldik LJ, Mattson MP. S100 beta protects hippocampal neurons from damage induced by glucose deprivation. Brain Res 1995;677:167-170.
42. Marks A, O ' Hanlon D, Lei M, Percy ME, Becker LE. Accumulation of S100 beta mRNA and protein in cerebellum during infancy in Down syndrome and control subjects. Brain Res Mol Brain Res 1996;36:343-348.